Acute gefitinib-induced pneumonitis

被引：29

作者：

Ohyanagi F. ^{[1
]}

Ando Y. ^{[1
]}

Nagashima F. ^{[1
]}

Narabayashi M. ^{[1
]}

Sasaki Y. ^{[1
]}

机构：

[1] Department of Clinical Oncology, Saitama Medical School, Iruma-gun, Saitama 350-0451, 38 Morohongo, Moroyama-machi

来源：

International Journal of Clinical Oncology | 2004年 / 9卷 / 5期

关键词：

Adverse effect; Gefitinib; Interstitial lung disease;

D O I：

10.1007/s10147-004-0418-0

中图分类号：

学科分类号：

摘要：

A 60-year-old woman with non-small cell lung cancer was treated with gefitinib and developed acute pneumonitis on the third day. Pulmonary damage and/or interstitial lung disease (ILD) related to gefitinib was diagnosed clinically and radiographically. Despite the immediate withdrawal of gefitinib and the administration of high-dose steroid, the patient did not fully recover and finally died of respiratory failure on day 22 after gefitinib had commenced. This case cautions us that careful monitoring provides no guarantee of safeguarding patients against ILD caused by gefitinib. We should make the decision to treat patients with gefitinib very carefully until we can elucidate which patients are at high risk and which patients are likely to have a response to this drug.

引用

页码：406 / 409

页数：3

共 9 条

[1]

Fukuoka M., Yano S., Giaccone G., Et al., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer, J Clin Oncol, 21, pp. 2237-2246, (2003)

[2]

Giaccone G., Herbst R.S., Manegold C., Et al., Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1, J Clin Oncol, 22, pp. 777-784, (2004)

[3]

Herbst R.S., Giaccone G., Schiller J.H., Et al., Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2, J Clin Oncol, 22, pp. 785-794, (2004)

[4]

Inoue A., Saijo Y., Maemondo M., Et al., Severe acute interstitial pneumonia and gefitinib, Lancet, 361, pp. 137-139, (2003)

[5]

Cohen M.H., Williams G.A., Sridhara R., Et al., United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839

[6]

Iressa) tablets, Clin Cancer Res, 10, pp. 1212-1218, (2004)

[7]

Final Report on Interstitial Lung Disease (ILD) Related to Gefitinib (Iressa Tablet 250) by Iressa Expert Committee, (2003)

[8]

Shah N.T., Miller V.A., Kris M.G., Et al., Bronchioalveolar histology and smoking history predict response to gefitinib, Proc Am Soc Clin Oncol, 22, (2003)

[9]

Yano S., Kanematsu T., Miki T., Et al., A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa), Cancer Sci, 94, pp. 453-458, (2003)

← 1 →